# AbbVie immunology pipeline and strategic transition

> Live situation record from CLSTR: https://clstr.news/situations/abbvie-immunology-pipeline-and-strategic-transition
> Updated: 2026-09-10T20:14:48.000Z. Sources: 4. Developments: 2.

AbbVie is undergoing a strategic transition to mitigate the impact of biosimilar competition on its blockbuster drug, Humira. Following a decline in Humira sales to $6.4 billion in 2025, the company has relied on the growth of its immunology therapies, Skyrizi and Rinvoq, which generated $17 billion in combined sales during the same period.

To further strengthen its immunology and inflammation pipeline, AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics. This acquisition brings long-acting antibody programs into AbbVie’s portfolio, specifically targeting dermatologic and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A primary asset from the deal is zumilokibart, a monoclonal antibody that showed significant skin clearance in Phase 2 trials and is designed for potentially less frequent dosing schedules.

## Timeline

### 2026-09-10: AbbVie completes $10.9 billion acquisition of Apogee Therapeutics

AbbVie has finalized a $10.9 billion acquisition of Apogee Therapeutics, adding long-acting antibody programs for atopic dermatitis, asthma, and COPD to its immunology pipeline.

2 sources. https://clstr.news/cluster/abbvie-completes-109-billion-acquisition-of-apogee-therapeutics

### 2026-08-25: AbbVie manages Humira revenue decline with pipeline growth

AbbVie is countering the revenue decline of its Humira franchise caused by biosimilar competition through the rapid growth of its Skyrizi and Rinvoq immunology therapies.

2 sources. https://clstr.news/cluster/abbvie-manages-humira-revenue-decline-with-pipeline-growth

---
Cite as: AbbVie immunology pipeline and strategic transition. CLSTR, https://clstr.news/situations/abbvie-immunology-pipeline-and-strategic-transition